These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15717064)

  • 1. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.
    Pardridge WM
    NeuroRx; 2005 Jan; 2(1):129-38. PubMed ID: 15717064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.
    Zhang Y; Calon F; Zhu C; Boado RJ; Pardridge WM
    Hum Gene Ther; 2003 Jan; 14(1):1-12. PubMed ID: 12573054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.
    Zhang Y; Schlachetzki F; Zhang YF; Boado RJ; Pardridge WM
    Hum Gene Ther; 2004 Apr; 15(4):339-50. PubMed ID: 15053859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier.
    Pardridge WM
    Cold Spring Harb Protoc; 2010 Apr; 2010(4):pdb.prot5407. PubMed ID: 20360361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model.
    Lin CY; Hsieh HY; Chen CM; Wu SR; Tsai CH; Huang CY; Hua MY; Wei KC; Yeh CK; Liu HL
    J Control Release; 2016 Aug; 235():72-81. PubMed ID: 27235980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats.
    Zhang Y; Boado RJ; Pardridge WM
    J Gene Med; 2003 Dec; 5(12):1039-45. PubMed ID: 14661179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of PEGylated Immunoliposomes to Deliver Dopamine Across the Blood-Brain Barrier in a Rat Model of Parkinson's Disease.
    Kang YS; Jung HJ; Oh JS; Song DY
    CNS Neurosci Ther; 2016 Oct; 22(10):817-23. PubMed ID: 27350533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter.
    Xia CF; Boado RJ; Zhang Y; Chu C; Pardridge WM
    J Gene Med; 2008 Mar; 10(3):306-15. PubMed ID: 18085726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes.
    Zhang YF; Boado RJ; Pardridge WM
    Pharm Res; 2003 Nov; 20(11):1779-85. PubMed ID: 14661922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-brain barrier transport of non-viral gene and RNAi therapeutics.
    Boado RJ
    Pharm Res; 2007 Sep; 24(9):1772-87. PubMed ID: 17554608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference and nonviral targeted gene therapy of experimental brain cancer.
    Boado RJ
    NeuroRx; 2005 Jan; 2(1):139-50. PubMed ID: 15717065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex.
    Imaoka T; Date I; Ohmoto T; Nagatsu T
    Hum Gene Ther; 1998 May; 9(7):1093-102. PubMed ID: 9607420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Parkinson's - tyrosine hydroxylase and oxidative stress as points of interventions.
    Khan MS; Tabrez S; Priyadarshini M; Priyamvada S; Khan MM
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):369-80. PubMed ID: 22483312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase.
    Wu SP; Fu AL; Wang YX; Yu LP; Jia PY; Li Q; Jin GZ; Sun MJ
    Biochem Biophys Res Commun; 2006 Jul; 346(1):1-6. PubMed ID: 16762325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes.
    Shi N; Boado RJ; Pardridge WM
    Pharm Res; 2001 Aug; 18(8):1091-5. PubMed ID: 11587478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism.
    Segovia J; Vergara P; Brenner M
    Gene Ther; 1998 Dec; 5(12):1650-5. PubMed ID: 10023444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.
    Sun M; Zhang GR; Kong L; Holmes C; Wang X; Zhang W; Goldstein DS; Geller AI
    Hum Gene Ther; 2003 Mar; 14(5):415-24. PubMed ID: 12691607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes.
    Xia CF; Chu C; Li J; Wang Y; Zhang Y; Boado RJ; Pardridge WM
    J Gene Med; 2007 Jul; 9(7):605-12. PubMed ID: 17471587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intracerebral grafting of ex vivo transgene muscle cells in rat model of parkinsonism].
    Xu Q; Tian J; Zhang J
    Zhonghua Wai Ke Za Zhi; 1997 Jan; 35(1):5-9. PubMed ID: 10374497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier.
    Boado RJ; Pardridge WM
    J Drug Deliv; 2011; 2011():296151. PubMed ID: 22175028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.